Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,106

Employees15,106

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,106

Employees15,106

REGN Key Statistics

Market cap

61.28B

Market cap61.28B

Price-Earnings ratio

14.25

Price-Earnings ratio14.25

Dividend yield

0.31%

Dividend yield0.31%

Average volume

942.03K

Average volume942.03K

High today

$568.46

High today$568.46

Low today

$551.48

Low today$551.48

Open price

$558.39

Open price$558.39

Volume

844.51K

Volume844.51K

52 Week high

$1,211.20

52 Week high$1,211.20

52 Week low

$476.49

52 Week low$476.49

REGN News

Simply Wall St 55m

Accelerated FDA Approval of Lynozyfic May Change the Case for Investing in Regeneron

Regeneron Pharmaceuticals recently received accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed or refractory multiple mye...

TipRanks 14h

Regeneron Pharmaceuticals Launches Long-Term Follow-Up Study on Gene Modified T Cell Therapy

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium...

TipRanks 15h

Regeneron and Sanofi’s Dupixent® Study: Real-World Insights for Investors

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Don’t Miss TipR...

Analyst ratings

70%

of 27 ratings

Buy

70.4%

Hold

25.9%

Sell

3.7%

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.